Fate Therapeutics (NASDAQ: FATE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 18.75 percent increase over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $1.299 million which beat the analyst consensus estimate of $1.139 million by 14.05 percent. This is a 20.26 percent decrease over sales of $1.629 million the same period last year.